Emerging data suggest Retatru tide , a dual agonist targeting both GLP-1 and another hormone, may provide a significant step forward for obesity loss . Early patient trials have indicated considerable losses in abdominal fat , conceivably exceeding existing obesity therapies . Nevertheless , further assessment is necessary to thoroughly determine i